Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 13/20 | 0.84 |
| ▸ | RAD52 | P43351 | 2/20 | 0.83 |
| ▸ | BRD4 | O60885 | 8/20 | 0.74 |
| ▸ | BRDT | Q58F21 | 7/20 | 0.74 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.67 |
| ▸ | PLK3 | Q9H4B4 | 3/20 | 0.64 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.62 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.62 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.62 |
| ▸ | EGFR | P00533 | 2/20 | 0.62 |
| ▸ | FES | P07332 | 2/20 | 0.62 |
| ▸ | PHKG2 | P15735 | 2/20 | 0.62 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.62 |
| ▸ | CLK2 | P49760 | 2/20 | 0.62 |
| ▸ | NEK2 | P51955 | 2/20 | 0.62 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.62 |
| ▸ | CAMK2B | Q13554 | 2/20 | 0.62 |
| ▸ | CAMK2G | Q13555 | 2/20 | 0.62 |
| ▸ | CAMK2D | Q13557 | 2/20 | 0.62 |
| ▸ | PTK2B | Q14289 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1203960 | 0.94 | PLK1 (0.77) | PLK1RAD52BRD4BRDTALK | |
| SCHEMBL1203958 | 0.94 | PLK1 (0.77) | PLK1RAD52BRD4BRDTALK | |
| SCHEMBL12879963 | 0.94 | PLK1 (0.77) | PLK1RAD52BRD4BRDTALK | |
| SCHEMBL1202797 | 0.93 | PLK1 (0.86) | PLK1RAD52BRD4BRDTALK | |
| SCHEMBL1202517 | 0.93 | PLK1 (0.94) | PLK1RAD52BRD4BRDTALK | |
| SCHEMBL3543418 | 0.92 | PLK1 (0.85) | PLK1RAD52BRD4BRDTALK | |
| SCHEMBL3546059 | 0.92 | RAD52 (0.87) | PLK1RAD52BRD4BRDTALK | |
| SCHEMBL12880497 | 0.92 | PLK1 (0.84) | PLK1RAD52BRD4BRDTALK | |
| SCHEMBL619257 | 0.92 | PLK1 (1.00) | PLK1RAD52BRD4BRDTALK | |
| SCHEMBL3543471 | 0.91 | PLK1 (0.83) | PLK1RAD52BRD4BRDTALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150344486-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2015-12-03 | — | — | US | claimed |
| EP-2610256-A1 | Pyrimidine derivatives as protein kinase inhibitors | Cyclacel Limited (GB) | 2013-07-03 | — | — | EP | claimed |
| US-9493471-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2016-11-15 | — | — | US | disclosed |
| US-9493471-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2016-11-15 | — | — | US | disclosed |
| US-9493471-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2016-11-15 | — | — | US | disclosed |
| US-20150344486-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2015-12-03 | — | — | US | disclosed |
| US-20150344486-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2015-12-03 | — | — | US | disclosed |
| US-20150344486-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2015-12-03 | — | — | US | disclosed |
| US-9133199-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2015-09-15 | — | — | US | disclosed |
| US-9133199-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2015-09-15 | — | — | US | disclosed |
| US-9133199-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2015-09-15 | — | — | US | disclosed |
| US-20140066436-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | TETHRA BIOSCIENCES INC. | 2014-03-06 | — | — | US | disclosed |
| US-8563542-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2013-10-22 | — | — | US | disclosed |
| US-8563542-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2013-10-22 | — | — | US | disclosed |
| US-8563542-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2013-10-22 | — | — | US | disclosed |
| EP-2610256-A1 | Pyrimidine derivatives as protein kinase inhibitors | Cyclacel Limited (GB) | 2013-07-03 | — | — | EP | disclosed |
| US-20110046093-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2011-02-24 | — | — | US | disclosed |
| US-20110046093-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2011-02-24 | — | — | US | disclosed |
| US-7709471-B2 | Compounds | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| US-20080009482-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009482-A1 | NOVEL COMPOUNDS | CYP11B2, CYP11B1, CYP46A1 | PLK1 847/4885RAD52 4730/4885BRD4 2662/4885 |
| US-20110046093-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CDK7, CDK9, CDK8 | PLK1 355/4885RAD52 2823/4885BRD4 589/4885 |
| US-20140066436-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CDK7, CDK9, CDK8 | PLK1 349/4885RAD52 2882/4885BRD4 669/4885 |
| US-20150344486-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | DCK, DTYMK, TK1 | PLK1 23/4885RAD52 1278/4885BRD4 1149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.